CP-207 Analysis of effectiveness and safety of enzalutamide and abiraterone in patients with unresectable prostate adenocarcinoma resistant to castration

FJ Manzano Lista; AR Rubio Salvador; N Labrador Andújar; JM Martínez Sesmero; M García Palomo; J Mateos Rubio; JJ Cia Lecumberri; P Moya Gómez

doi:10.1136/ejhpharm-2016-000875.207

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via EAHP

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens
Log in via EAHP

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Alerts

Clinical pharmacy

CP-207 Analysis of effectiveness and safety of enzalutamide and abiraterone in patients with unresectable prostate adenocarcinoma resistant to castration

Log in using your username and password

Main menu

Log in using your username and password

You are here

Read the full text or download the PDF:

Log in using your username and password